NVO — Novo Nordisk A/S Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapFalling Star

Annual income statement for Novo Nordisk A/S, fiscal year end - December 31st, DKK millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	126,946	140,800	176,954	232,261	290,403
Cost of Revenue
Gross Profit	106,014	117,142	148,506	196,496	246,843
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	72,820	82,156	102,145	129,687	162,064
Operating Profit	54,126	58,644	74,809	102,574	128,339
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	53,130	59,080	69,062	104,674	127,191
Provision for Income Taxes
Net Income After Taxes	42,138	47,757	55,525	83,683	100,988
Net Income Before Extraordinary Items
Net Income	42,138	47,757	55,525	83,683	100,988
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	42,138	47,757	55,525	83,683	100,988
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	9.08	10.5	12.4	19	24.5
Dividends per Share